Immune to Cancer: The CRI Blog
-
AACR17 Update: Checkpoint Immunotherapy Clinical Trials in Melanoma and Lung Cancer
In-depth analysis of long-term clinical trial data provides important insights for doctors treating…
-
Pembrolizumab (Keytruda®) Approved as First-Line Option for Lung Cancer
Anti-PD-1 checkpoint antibody is the only immunotherapy approved for first-line treatment for lung cancer patients.
-
FDA Approves Another Immunotherapy Option for Patients with Advanced Lung Cancer
Anti-PD-L1 atezolizumab is the second PD-1 pathway drug approved for lung cancer this month.
-
Checkpoint Inhibitors Benefit Lung Cancer Patients in Clinical Trials
Patients with metastatic non-small cell lung cancer could soon have a new first-line immunotherapy treatment option.
-
ASCO 2016 Update: Advances in Immunotherapy for Lung and Blood Cancers
Combination checkpoints, improved CAR T cells show promise.
-
FDA Approves Expanded Use of Nivolumab for Lung Cancer
Nivolumab, a PD-1 immunotherapy, is now approved as second-line therapy for the most common type of lung…
-
FDA Approves PD-1 Immunotherapy for Most Common Type of Lung Cancer
Patients with non-small cell lung cancer may now receive a PD-1 immunotherapy as second-line treatment after chemotherapy.
-
What Patients Need to Know About Lung Cancer Immunotherapy
Join us on August 21 as Julie Brahmer, MD, discusses the latest research and current treatments for…
-
New Clinical Trials to Offer Immunotherapy as Frontline Treatment for Lung Cancer
Patients with lung cancer will soon be able to receive immunotherapy as first-line treatment on an experimental…